Highly active ms treatment. It is characterized by brain and spinal cord involvement.



Highly active ms treatment. Apr 23, 2018 · This article presents the recommendations and suggestions for future research of an American Academy of Neurology (AAN) practice guideline on the efficacy and safety of disease-modifying therapies (DMTs) in multiple sclerosis (MS). Experts have determined that people with highly active MS should start HE DMTs earlier to reduce the impact of MS on their lives. Mar 3, 2023 · Some studies consider aggressive MS and highly active MS as part of the same spectrum with different degrees of severity, while other authors regard them as different entities (3, 5). Aug 9, 2025 · Background Comparative assessments of all available disease-modifying therapies (DMTs) in patients with highly active relapsing-remitting multiple sclerosis (RRMS) are lacking, even though some of these DMTs are restricted to this MS subpopulation. Apr 7, 2023 · Highly active MS often is associated with a poor prognosis, including incomplete recovery from relapses and a shorter time between relapses. However, aggressive and highly active MS share features such as (a) frequent relapses, sometimes with incomplete A R T I C L E I N F O Keywords: Review Multiple sclerosis Highly active multiple sclerosis A B S T R A C T Multiple sclerosis (MS) is the most prevalent chronic inflammatory disease of the central nervous system (CNS), afecting more than 2 million people worldwide. Nov 9, 2018 · In the past, this disease phenotype was called "aggressive" MS (AMS); it is now called highly active MS (HAMS). It is generally agreed that the severe nature of this phenotype requires different treatment decisions. While aggressive MS can shorten life expectancy, many patients live several years with the disease, especially with effective management. Keywords: Aggressive, highly active, multiple sclerosis, disability, relapsing–remitting, treatment response Introduction Retrospective observational studies have suggested that an early highly effective treatment approach is more beneficial in patients with highly active MS; however, the impact of these treatment paradigms on patients with mild to moderately active disease remains unknown. eo 2a enltvyy co5mu 3h bgwi syru a9xnwy zqgae y9fy